Lectin-related use of mistletoe: An experimental form of treatment with preclinically demonstrated potential risks;Lektinbezogene mistelanwendung: Experimentelle therapieform mit präklinisch belegtem risikopotenzial

Deutsche Medizinische Wochenschrift

Volumn 127, Issue 9, 2002, Pages 457-459

  Gabius, S ^a   Gabius, H J ^a  

^a Internistische Onkologie   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

LECTIN;

CANCER RISK; DRUG EFFECT; MELANOMA; MONONUCLEAR CELL; NOTE; RISK ASSESSMENT; VISCUM ALBUM;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; HUMANS; LECTINS; MICE; MICE, INBRED C3H; MISTLETOE; NEOPLASMS; PHYTOTHERAPY; PLANT LECTINS; PLANT PREPARATIONS; PLANT PROTEINS; RATS; RISK FACTORS; TOXINS, BIOLOGICAL; TUMOR CELLS, CULTURED;

EID: 0036499778     PISSN: 00120472     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2002-20425     Document Type: Note

References (24)

1. 1st die mistel eine altes krebsheilmittel?
2. Begutachtung »unkonventioneller« maßnahmen bei malignen tumorerkrankungen in der gesetzlichen krankenversicherung
3. European Organization for Research and Treatment of Cancer Melanoma Group trial experience with more than 2,000 patients, evaluating adjuvant treatment with low or intermediate doses of interferon α-2b
4. Mistelextrakte in der krebstherapie
5. Immunmodulierende misteltherapie durch lektinstandardisierung: Ein zweischneidiges schwert?
6. The galactoside-specific lectin from mistletoe as biological response modifier
7. Evidence for stimulation of tumor proliferation in cell lines and histotypic cultures by clinically relevant low doses of the galactoside-binding mistletoe lectin, a component of proprietary extracts
8. Modulatory potency of the galactoside-specific lectin from mistletoe extract (Iscador®) on the host defense system in vivo in rabbits and patients
9. Increased secretion of tumor necrosis factor-α, interleukin-1, and interleukin-6 by human mononuclear cells exposed to galactoside-specific lectin from clinically applied mistletoe extract
10. Subkutane manifestationen eines zentrozytischen non-Hodgkin-lymphoms an injektionsstellen eines mistelpräparates
11. Leserzuschrift
12. Mistelextrakt (Iscador u.a.): Zurück in die präklinische prüfung?
13. Kann die misteltherapie anhand von zytokinwirkungen interpretiert werden?
14. Inability of galactoside-specific mistletoe lectin to inhibit N-methyl-N-nitrosourea-induced tumor development in the urinary bladder of rats and to mediate a local cellular immune response after long-term administration
15. Long-term administration of galactoside-specific mistletoe lectin in an animal model: No protection against N-butyl-N-(4-hydroxybutyl)-nitrosamine-induced urinary bladder carcinogenesis in rats and no induction of a relevant local cellular immune response
16. Der arzneirechtliche rahmen der beurteilung der wirksamkeit von arzneimitteln
17. Der ätherleib zwischen kosmos und erde
18. Onkologische misteltherapie - Zur anwendung und bewertung der wirksamkeit durch ärzte
19. Die mistel in der krebsbehandlung - Möglichkeiten und grenzen
20. Zum problem der »Binnenanerkennung« von besonderen therapierichtungen
21. Immunotherapy of C3H/HeJ mammary adenocarcinoma with interleukin-2, mistletoe lectin or their combination: Effects on tumor growth, capillary leakage and nitric oxide (NO) production